118 results
10-K
2019 FY
ORTX
Orchard Therapeutics plc
27 Feb 20
Annual report
4:02pm
and/or receive rescue bone marrow transplant.
In the European Union, our commercial program Strimvelis is available as the only approved gene therapy option … to the European Union registration, we are preparing the BLA for OTL-200. A pre-BLA application has been filed in order to present and discuss
10-Q
u7xk1w4i79xtnf4cqbm
7 May 20
Quarterly report
4:03pm
20-F
c1hi7mowx
22 Mar 19
Annual report (foreign)
8:02am
424B4
4dpxw39a1z
31 Oct 18
Prospectus supplement with pricing info
4:36pm
F-1/A
mf7 zbu1gl
23 Oct 18
Registration statement (foreign) (amended)
6:15am
F-1
4fn zker6
4 Oct 18
Registration statement (foreign)
4:48pm
DRS
0hjljt
6 Aug 18
Draft registration statement
12:00am
8-K
EX-10.2
1cn0h
20 Mar 20
Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
4:11pm
8-K
EX-99.1
ttebest
14 Jan 21
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200
7:03am
8-K
EX-99.2
bbax2 sylyn
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
8-K
EX-99.1
99fdr rix
21 Jan 22
Other Events
7:05am
6-K
EX-99.1
nb6ttag0tuu
6 Jun 19
Orchard Therapeutics Launches Proposed Public Offering
4:31pm
8-K
EX-99.1
gb3 7l0xkac3
19 Nov 20
Other Events
7:03am